8-K: DataMeds AI Secures IP License, Addresses Nasdaq Listing

DataMeds AI, Inc. has entered into a material intellectual property license agreement and taken steps to regain compliance with Nasdaq's minimum stockholders equity requirement.

Summary

• DataMeds AI, Inc. has entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc. on October 13, 2026.
• This agreement grants DataMeds an exclusive license in the U.S. for REBOOT's AI platform for its GLP-1 weight management business, specifically for its direct-to-consumer model.
• DataMeds issued 666,667 shares of common stock to REBOOT as part of the agreement, valued at $2,000,000, with potential for additional shares if the market value falls below this threshold within 180 days.
• The company also agreed to pay $50,000 upfront for platform reconfiguration, estimated to cost a minimum of $100,000.
• The company has taken actions, including converting vendor payables to stock and issuing shares for an acquisition, to increase its stockholders equity.
• These actions, along with the IP license stock component, are believed to have brought the company's stockholders equity above the $2,500,000 minimum required by Nasdaq.
• DataMeds is awaiting Nasdaq's formal confirmation of compliance for continued listing on The Nasdaq Capital Market.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company has secured a crucial IP license and addressed a critical listing deficiency, though significant revenue sharing and ongoing compliance monitoring remain.

Positives

• Secured an exclusive U.S. license for REBOOT Health AI's platform for its GLP-1 weight management business.
• Addressed and potentially resolved the Nasdaq minimum stockholders equity deficiency, increasing equity through various transactions.
• Completed a settlement that extinguished approximately $18.7 million of debt.
• Issued 666,667 shares of common stock valued at $2,000,000 as consideration for the IP license, demonstrating commitment.
• The IP license agreement continues in perpetuity, subject to certain conditions, providing long-term access to technology.

Negatives

• REBOOT retains all rights to the REBOOT Platform and DataMeds Platform, including source code, and DataMeds cannot modify, reconfigure, reverse engineer, or create derivative works.
• A significant portion of revenue generated from the use of REBOOT technology will be shared with REBOOT through a Revenue Sharing Agreement.
• The company must issue additional shares if the market value of the initial stock issuance falls below $2,000,000 after 180 days.
• The company is still awaiting formal confirmation from Nasdaq regarding its compliance with listing requirements.
• There is a risk of delisting proceedings if the company does not evidence compliance with the stockholders equity requirement at the time of its next periodic report.

Risks

• Potential delisting proceedings if stockholders equity compliance is not maintained after the next periodic report.
• The exclusive license is limited to DataMeds' direct-to-consumer GLP-1 weight management business and excludes direct sales to healthcare providers.
• REBOOT retains ownership of the platform and its reconfigurations, limiting DataMeds' control and ability to innovate independently.
• The revenue sharing agreement with REBOOT will reduce the net revenue generated from the licensed technology.
• The company may need to issue additional shares to REBOOT if the initial stock component's market value declines, potentially diluting existing shareholders.

Future Outlook

The company believes it has met the minimum stockholders equity requirement for continued listing on Nasdaq and awaits formal confirmation. Nasdaq will continue to monitor compliance, and failure to meet the requirement in the next periodic report could lead to delisting proceedings. The IP license agreement is perpetual, subject to termination for breach or failure to meet minimum revenue thresholds.

Management Comments

• The Company believes that, as a result of the foregoing transactions, it has in excess of $2,500,000 in stockholders equity as required under Nasdaq Listing Rule 5550(b)(1).
• The Company awaits Nasdaq's formal confirmation that it has evidenced compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that securing intellectual property licenses, especially for AI-driven platforms in the health tech sector, is a common strategy for companies aiming to differentiate and scale. However, the terms of such licenses, including revenue sharing and restrictions on modification, are critical to evaluating their long-term value. The company's efforts to meet Nasdaq's listing requirements highlight the ongoing challenges faced by early-stage or financially constrained companies in maintaining public market access.

Related Party Transactions

• The IP License Agreement with REBOOT Health AI, Inc. involves the issuance of company stock and a revenue sharing agreement, which are related party transactions.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of shares to REBOOT Health AI, Inc. and potential additional shares if the stock value declines. However, maintaining Nasdaq listing is positive for shareholder value.
• Creditors: The settlement of $18.7 million in debt is a positive development for creditors, reducing the company's liabilities.
• Suppliers: Conversion of $1.5 million in vendor payables to common stock may impact suppliers who received stock instead of cash.

Next Steps

• Await Nasdaq's formal confirmation of compliance with listing requirements.
• Continue to monitor stockholders equity compliance for future periodic reports.
• Implement the REBOOT Health AI platform within the Company's GLP-1 weight management business.
• Manage the revenue sharing agreement with REBOOT Health AI, Inc.

Key Dates

Recommendation

The company has taken critical steps to address its Nasdaq listing deficiency and secure essential intellectual property. However, the significant revenue sharing obligations, the ongoing reliance on a third party for platform technology, and the need for continued Nasdaq compliance monitoring introduce considerable risk. While these actions are positive, they do not yet guarantee sustained growth or profitability, warranting a cautious 'hold' stance until further operational and financial performance is demonstrated.

Keywords

Intellectual Property License, Product and Services Agreement, GLP-1 Weight Management, REBOOT Health AI, Nasdaq Listing Compliance, Stockholders Equity, Revenue Sharing Agreement, DataMeds Platform